Nano Research & Applications

GMP manufacturing of nanomedicines for clinical trials

EuroSciCon Conference on Nanotechnology & Smart Materials
October 04 -06 ,2018 Amsterdam , Netherlands

Silvie A Meeuwissen

Ardena-ChemConnection B V, The Netherlands

ScientificTracks Abstracts: Nano Res Appl

DOI: 10.21767/2471-9838-C6-024

Abstract

Nanomedicine, the convergence between nanotechnology and medical application, is a hot field. Many research groups all around the world focus their efforts on the invention of potential new nanomaterials that can contribute to improved health care. The nanoscale physical properties of these particles afford a unique potential for biomedical application in the treatment of e.g. cancer, brain, inflammatory and immune diseases. Despite their great potential, the far majority of all discovered nanomedicines are still at the research stage. To bring the discovery from laboratory bench to patient bedside requires a whole different discipline: pharmaceutical development. This presentation will give the audience a sneak peek of what it takes to navigate a potential nanomedicine through the world of drug development. Special attention will be given to the translation from lab experiments to production of nanomedicine intended for use in humans

Biography

Silvie A Meeuwissen has received a PhD in Bioorganic Chemistry from Radboud University in Nijmegen, under the supervision of Prof Jan van Hest in 2013. Her research is focussed on polymer chemistry and the creation, analysis and application of nanocarriers. She worked on a Postdoctoral project at Future Chemistry in cooperation with the Synthetic Organic Chemistry Group of Prof Floris Rutjes (RU Nijmegen), before she started as a Researcher at ChemConnection in 2014. ChemConnection, part of the Ardena group, is a contractor for all chemical, pharmaceutical and bioanalytical needs that arise in the clinical supply chain from lab to patient. Currently, she is working as a Principal Scientist and manages several projects, focusing on process development and GMP manufacture of novel nanomedicine candidates for preclinical trials.

E-mail: silvie.meeuwissen@ardena.com